Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Eczema (Atopic Dermatitis)

Also known as: eczema, atopic dermatitis, dermatitis

Atopic dermatitis, also called atopic eczema, is a chronic relapsing itchy inflammatory skin disease diagnosed on clinical criteria, involving epidermal barrier dysfunction and immune activation. It is a medical diagnosis made by a clinician, not a skin type, a dryness state, or a condition treatable in a beauty setting.

Evidence status

Strong

Diagnosis and first-line management are supported by NICE guidance, large UK NIHR-funded RCTs and Cochrane individual-participant-data meta-analyses. Prevention is different: BEEP and Cochrane found that infant emollient use did not reduce eczema and probably increased skin infections; the five-year eczema outcome was parent-reported, and CG57 covers only under-12s because NICE stopped adult/adolescent guideline development in 2023. No trial evaluates peels, microneedling or professional facials on active atopic dermatitis, so caution rests on clinical guidance about irritants, infection and an inflamed barrier rather than procedure trials.

What atopic dermatitis is, and how it presents#

Atopic dermatitis, also called atopic eczema, is a chronic relapsing inflammatory disease characterised by itch, eczematous lesions and periods of flare and remission. Diagnosis is clinical. It cannot be established from a barrier scan, TEWL reading, retail consultation or the presence of dry skin alone.

NICE CG57 provides diagnostic criteria for children under 12: an itchy skin condition plus at least three specified features involving distribution or history, recent dry skin, atopic history and age at onset. Those criteria belong to paediatric clinical diagnosis, not a checklist for non-medical practitioners. There is no equivalent NICE clinical guideline for adolescents and adults; development of one was stopped in 2023, prompting a joint objection from eight UK professional and patient organisations.[1, 12]

Presentation is not always the familiar red flexural rash shown on light skin. NICE notes that Asian, Black Caribbean and Black African children may have extensor involvement and more discoid or follicular patterns. Erythema may also be harder to appreciate in deeper skin tones, so itch, texture, warmth, oedema, excoriation, oozing and change from baseline matter. The NICE statement is paediatric and should not be silently generalised into an adult diagnostic rule.[1]

Atopic dermatitis is common and can have substantial sleep, psychological and economic effects. UK professional bodies estimate that it affects around 20% of children and 10% of adults; the British Association of Dermatologists phrases the childhood estimate as “up to one in five”.[12, 13]

Use of eczema recognition in aesthetic practice#

The legitimate role is recognition, non-aggravation and referral, not diagnosis or medical treatment. A practitioner may document what is visible, ask about an established diagnosis and current prescribed plan, avoid known triggers, use only suitable cosmetic barrier support on clear skin, and communicate concerns to the client’s clinician.

Active disease is not an indication for a peel, microneedling, extraction, steam, abrasive facial or heat-based device. Between flares, an established history still calls for a conservative product assessment, because the procedure-specific flare risk has not been quantified.

Emollients are foundational in medical management, but NICE prescribing detail is not a salon protocol. Product status matters: a cosmetic may claim to moisturise or support the barrier, but a claim to treat or prevent eczema is medicinal. Topical corticosteroids are medicines. Recommending potency, changing use, calculating dose, tapering or advising cessation belongs with the prescriber. The fingertip-unit evidence and clinical dosing guidance exist for medical use, not for repackaging as aesthetic advice.[1][1][9, 13][8, 14]

England’s proposed non-surgical cosmetic licensing tiers do not create authority to diagnose or treat dermatological disease, and no such licensing scheme is currently in force.[14]

Contraindications and cautions#

An elective aesthetic procedure is inappropriate on skin that is actively inflamed, weeping, crusted, eroded, excoriated or suspected to be infected. This caution is inferred from the damaged, irritant-sensitive and infection-prone state described in clinical guidance; it has not been tested in peel, microneedling or facial trials.[1, 13]i

An unexpectedly changing previously stable eruption, spread after a product, eye involvement, pain, grouped blisters, punched-out erosions, fever or systemic illness warrants pausing elective treatment and medical referral. A reaction to a new topical product raises allergic or irritant contact dermatitis as a differential.

Fear of thinning or withdrawal is not a sound basis for advising cessation of prescribed topical corticosteroids. The MHRA concluded that these medicines are safe and effective when used correctly, while recognising that withdrawal reactions can occur after long-term continuous or inappropriate use, especially with moderate-to-high potency products and on delicate sites. Frequency cannot be estimated.[8]

“Natural”, botanical and fragranced products are not automatically gentler. In a 2026 meta-analysis, atopic dermatitis was not associated with contact sensitisation overall, but Compositae and sesquiterpene-lactone mixes—botanical allergen groups—did show associations.[11]

That review was funded by the Danish Environmental Protection Agency; one co-author also holds an affiliation with a commercial contact-allergen and patch-testing enterprise.[11]

Emollient residue on clothing and bedding presents a fire hazard. That warning applies regardless of whether the emollient itself is flammable in the container.[1, 13]

The British Association of Dermatologists states that insufficient treatment with topical steroids is generally considered by doctors to be more of a problem than overuse — clinical opinion in a patient leaflet, not a measured comparison.[13]

Clinical uses and the evidence behind them#

Recognition and timely referral. NICE provides explicit paediatric referral thresholds, including same-day assessment for suspected eczema herpeticum and referral where diagnosis is uncertain, facial disease is unresponsive, contact allergy is suspected or psychosocial impact is significant. These are useful safety boundaries even though the guideline is for under-12s.[1]

Barrier support for established eczema. Emollients are a core part of medical management. A pragmatic trial of 550 English children compared lotions, creams, gels and ointments for 16 weeks and found no difference in eczema severity between formats (global p=0.77). Stinging was lower with ointments—9% versus 17–20% with the other formats—but no format was universally superior. The result supports individual acceptability rather than formulation ideology and does not compare specific ingredients such as ceramides.[7]

Primary prevention is a different question. A Cochrane individual-participant-data review found that infant skin-care interventions probably did not change eczema risk at one to three years (RR 1.03, 95% CI 0.81–1.31; moderate certainty) and probably increased skin infection (RR 1.33, 95% CI 1.01–1.75). In the 1,394-infant BEEP trial, eczema occurred in 23% of the emollient group and 25% of controls at age two (adjusted RR 0.95, 95% CI 0.78–1.16), while skin infections were more frequent (incidence-rate ratio 1.55, 95% CI 1.15–2.09). At five years, parent-reported clinical diagnosis of eczema remained similar: 31% versus 28% (adjusted RR 1.10, 95% CI 0.93–1.30). These prevention results do not undermine emollients for symptom management after eczema exists.[2, 3, 4][2, 3, 4]

Several Cochrane-review authors also investigated trials included in that review. BEEP was NIHR-funded with no emollient-manufacturer funding; authors disclosed several unrelated pharmaceutical interests.[2, 3, 4]

Professional procedures. No clinical trial, cohort or case series was located evaluating chemical peels, microneedling, LED, radiofrequency or professional facial treatments in people with active or recently active atopic dermatitis. Absence of evidence is not evidence that barrier-disrupting treatment is safe.

Selecting appropriate barrier support#

Selection begins with disease state and product status. Active disease, suspected infection or diagnostic uncertainty goes to medical care. On clear skin between flares, use the person’s established clinical plan as the anchor and avoid introducing multiple products at once.

For a cosmetic moisturiser, consider ingredient list, fragrance and botanical allergens, texture, site, previous tolerance and manufacturer directions. No lotion, cream, gel or ointment format proved superior overall in the paediatric BEE trial, so tolerability and consistent use matter.[7] Aqueous cream is not recommended by the BAD as a leave-on moisturiser because it may irritate and worsen eczema.[13]

A flare following a newly introduced product should prompt discontinuation of that suspected exposure, documentation of the exact product and timing, and medical assessment where persistent or significant. NICE asks clinicians to consider allergic contact dermatitis when previously controlled eczema exacerbates or reactions occur to topical treatments.[1] Patch testing is a medical diagnostic investigation for delayed hypersensitivity, not the same as a salon product-tolerance check.

A cosmetic recommendation is not a substitute for prescribed care. Questions about topical steroids, calcineurin inhibitors, infection treatment or systemic therapy belong with the prescriber.

Adverse effects and their management#

Cosmetic products can sting, irritate or cause allergic contact dermatitis. A suspected product reaction warrants cessation and safe removal of the product, documentation of the exposure and assessment of whether urgent or routine medical care is required. Persistent swelling, blistering, widespread dermatitis, facial or eye involvement, infection signs or systemic symptoms need medical review.

Emollients may cause stinging, folliculitis, contact reactions and slip hazards; residue on fabric increases fire risk. The comparative paediatric emollient trial found overall adverse-event rates of 35–40% across formats, with lower stinging for ointments but no overall difference.[7]

Topical corticosteroid adverse effects and withdrawal concerns must be managed by clinicians. Steroid fear is associated with poorer adherence: a systematic review found reported phobia prevalence ranging from 21.0% to 83.7%, with heterogeneous definitions, and the two comparative studies found markedly higher non-adherence in fearful groups. A practitioner should neither dismiss a concern nor recommend an unsupervised reduction.[10]

Eczema herpeticum is a medical emergency pattern. Sudden painful monomorphic vesicles or punched-out erosions on eczematous skin, particularly with systemic illness, require same-day referral rather than product management.[1]

Referral and scope boundaries#

Same-day medical assessment is required for suspected eczema herpeticum. Urgent assessment is also appropriate for significant systemic illness, rapidly spreading painful disease, eye involvement or severe infection.

Prompt or routine referral is appropriate when:

  • the diagnosis is uncertain;
  • active disease is weeping, crusted, pustular or not responding to the existing clinical plan;
  • facial eczema persists or worsens;
  • a previously controlled condition flares after a topical exposure;
  • allergic contact dermatitis is suspected;
  • prescribed treatment is causing concern or a change is being considered;
  • sleep, work, school or psychological wellbeing is substantially affected.

NICE’s detailed timing thresholds are paediatric and directed to clinicians, but the warning patterns are useful to practitioners who need to stop and escalate.[1]

Non-medical aesthetic scope includes recognising these patterns, declining unsafe treatment, avoiding aggravating exposures and supporting a clinician-led plan on clear skin. It does not include writing “atopic dermatitis” as a new diagnosis, recommending medicines, changing prescribed treatment, treating infection or selling a cosmetic with an eczema-treatment claim.

Mechanism of action#

Atopic dermatitis reflects interaction between epidermal barrier dysfunction, immune dysregulation, environmental exposures and microbial factors. It is not reducible to “dry skin”.

Loss-of-function variants in FLG, the gene encoding filaggrin, strongly support a causal barrier contribution. A meta-analysis of 24 eczema studies, including 5,791 cases and 26,454 controls, found an odds ratio of 3.12 (95% CI 2.57–3.79) for eczema with FLG haploinsufficiency. The founding association work identified common null variants carried by approximately 9% of people of European origin, a figure that does not generalise across ancestries.[5, 6]

A three-fold increase in odds is not determinism. Many people with eczema do not carry those variants, and many carriers do not develop severe disease. Genotype also did not modify the null effect of infant skin-care prevention interventions.[2, 5, 6]i

Emollients reduce dryness and support the stratum-corneum barrier after disease exists, but that mechanism did not translate into prevention when basic emollients were applied from birth in high-risk infants.[2, 3, 4] Barrier biology therefore informs management without proving every “barrier-first” prevention claim.

Commonly misstated claims#

“Moisturising a high-risk baby from birth prevents eczema”

The Cochrane review and BEEP trial found no preventive benefit; both found an increased skin-infection signal.[2, 3, 4] Supported statement: Basic daily emollient use from birth has not prevented eczema in high-risk infants and probably increases skin infections.

“Ointments work better than creams, gels and lotions”

In 550 children, eczema severity did not differ across the four formats, although ointments stung less often.[7] Supported statement: No emollient format was superior overall; selection should account for tolerance and likelihood of use.

“Eczema means the person is allergic to skincare”

A meta-analysis found no overall association between atopic dermatitis and contact sensitisation (OR 1.08, 95% CI 0.82–1.42), although some age and botanical-allergen subgroups differed. Supported statement: Atopic dermatitis does not imply general contact allergy, but a product-linked flare can warrant clinical assessment and patch testing.[1, 11]

“Topical steroids are unsafe and should be stopped quickly”

The MHRA concluded that correctly used topical corticosteroids are safe and effective, while recognising rare but potentially debilitating withdrawal reactions after prolonged continuous or inappropriate use.[8] Supported statement: Topical corticosteroids require correct prescriber-led use; concerns and changes belong with the clinician.

“A salon facial can repair active eczema”

No clinical evidence was located for professional facials, peels or microneedling in active atopic dermatitis. Supported statement: Active eczema is medical, inflamed skin and should not be treated with an aesthetic procedure.

Areas of remaining uncertainty#

  • Flare risk from an aesthetic procedure on clear skin in someone with an eczema history has not been quantified, and no evidence-based post-flare interval or “barrier-ready” threshold exists; do not present a clinic rule as a validated safety threshold.
  • Whether a different infant intervention, such as a ceramide-dominant or acidified formulation, could prevent eczema is unresolved; BEEP tested basic paraffin-based products, so do not generalise the proven negative to every future formulation or market an untested alternative as preventive.[2, 3, 4]
  • The incidence, mechanism and diagnostic boundaries of topical steroid withdrawal remain uncertain, and the MHRA cannot estimate its frequency; acknowledge concerns but direct medication decisions to the prescriber.[8]
  • The overall contact-sensitisation result conceals age-, setting- and allergen-specific differences, and professional skincare exposures were not studied; investigate product-linked flares individually rather than labelling all atopic skin “allergic”.[11]
  • England’s eventual licensing framework and any dermatological-screening requirements remain undecided; check current law and local governance rather than treating the proposed tiers as operative.[14]

Frequently asked questions#

Can an aesthetic practitioner diagnose eczema?

No. The practitioner can recognise a pattern, describe observable findings and recommend medical assessment. Atopic dermatitis is a clinical diagnosis.

Can a facial be performed during a flare?

No elective procedure should be performed on actively inflamed, weeping, crusted, infected or excoriated skin. Direct procedure trials were not located; the decision rests on medical scope and barrier safety rather than proof of benefit.

Are emollients evidence-based?

Yes for barrier support and symptom management within an eczema plan. They did not prevent eczema when applied from birth to high-risk infants, which is a different question.[1, 2, 3, 4]

Should prescribed steroids be stopped before treatment?

That decision belongs to the prescriber. An aesthetic practitioner should not recommend stopping, tapering or changing a topical corticosteroid.[8]

When is eczema an emergency?

Suspected eczema herpeticum—typically sudden painful, similar-looking vesicles or punched-out erosions on eczematous skin—requires same-day medical assessment.[1]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management. NICE clinical guideline CG57. Published 12 December 2007; last updated 22 September 2025.Tier 1Supports: Scope is children from birth up to 12 years only; there is no equivalent NICE guideline for adults or adolescents. Diagnosis (1.1.1.2): 'Diagnose atopic eczema when a child has an itchy skin condition plus 3 or more of the following: visible flexural dermatitis... previous flexural dermatitis... dry skin in the last 12 months; asthma or allergic rhinitis (or history of atopic disease in a first-degree relative of children aged under 4 years); onset of signs and symptoms under the age of 2 years (do not use this criterion in children aged under 4 years).' NOTE THE PARSING TRAP, which the package originally got wrong: 'aged under 4 years' qualifies the CHILD BEING ASSESSED, not the first-degree relative. Skin-of-colour note, verbatim: 'in Asian, Black Caribbean and Black African children, atopic eczema can affect the extensor surfaces rather than the flexures, and discoid (circular) or follicular (around hair follicles) patterns may be more common.' Stepped treatment (table 2): mild = emollients + mild-potency topical corticosteroids; moderate = emollients + moderate-potency TCS + topical calcineurin inhibitors + bandages; severe = emollients + potent TCS + TCIs + bandages + phototherapy + systemic therapy. Emollients: 'Prescribe large quantities of leave-on emollients (250 g to 500 g weekly)'; apply 'on their whole body, both when the atopic eczema is clear and while using all other treatments'; if using emollient plus another topical, 'apply one product at a time, and wait several minutes'. 'Do not offer emollient bath additives to children with atopic eczema. [2023]' (1.5.1.11) — but read it against 1.5.1.10 in the same section, which still says 'leave-on emollients can be added to bath water'. NICE bans the proprietary bath-additive product category, not the act of putting emollient in the bath; omitting the second half overstates the restriction. Topical corticosteroid potency (1.5.1.13): mild for mild, moderate for moderate, potent for severe; 'use mild potency for the face and neck, except for short-term (3 to 5 days) use of moderate potency for severe flares'; moderate or potent 'for short periods only (7 to 14 days)' at axillae and groin; no very potent preparations in children without specialist advice; no potent TCS under 12 months without specialist supervision. Apply TCS 'only to areas of active atopic eczema (or eczema that has been active within the past 48 hours), which may include areas of broken skin'. Triggers (1.4.1.1) include 'irritants, for example soaps and detergents (including shampoos, bubble baths, shower gels and washing-up liquids)', skin infections, contact allergens, food allergens, inhalant allergens. 1.4.1.4: 'Consider a diagnosis of allergic contact dermatitis in children with: an exacerbation of previously controlled atopic eczema, or reactions to topical treatments.' 1.4.1.6: 'Advise children with atopic eczema and their parents or carers not to use high street or internet allergy tests, because there is no evidence of their value.' Referral: same-day if eczema herpeticum suspected; within 2 weeks if severe eczema unresponsive to optimal topical therapy after 1 week, or if treatment of bacterially infected eczema has failed; routine referral if diagnosis uncertain, facial eczema unresponsive, contact allergic dermatitis suspected, or significant psychosocial impact. Also carries an MHRA warning that emollient residue on clothing and bedding is a fire hazard. SCOPE LIMIT: paediatric; recommendations are directed at prescribing clinicians, not at non-medical skincare practitioners.
  2. Kelleher MM, Phillips R, Brown SJ, Cro S, Cornelius V, Lødrup Carlsen KC, Skjerven HO, Rehbinder EM, Lowe AJ, Dissanayake E, et al. Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews. 2022 Nov 14;11(11):CD013534. PMID 36373988.Tier 1Supports: Prospective individual-participant-data meta-analysis. 33 RCTs, 25,827 participants identified; 17 studies (5,823 participants) reported relevant outcomes; 11 studies (5,217 participants) entered at least one meta-analysis, 10 supplying IPD. Population: healthy term (>37 weeks) infants aged 12 months or under, without pre-existing eczema or food allergy. Key results: skin care interventions during infancy 'probably do not change the risk of eczema by one to three years of age (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; risk difference 5 more cases per 1000 infants, 95% CI 28 less to 47 more; moderate-certainty evidence; 3075 participants, 7 trials)' and do not change time to onset (HR 0.86, 95% CI 0.65 to 1.14; moderate certainty; 3,349 participants, 9 trials). Harms: interventions 'probably increase risk of skin infection over the intervention period (RR 1.33, 95% CI 1.01 to 1.75; risk difference 17 more cases per 1000 infants, 95% CI one more to 38 more; moderate-certainty evidence; 2728 participants, 6 trials)'; may increase IgE-mediated food allergy (RR 2.53, 95% CI 0.99 to 6.49; LOW certainty, 976 participants, ONE trial); may increase stinging or allergic reactions to moisturisers (RR 2.24, 95% CI 0.67 to 7.43; low certainty, 343 participants, 4 trials — CI includes no effect); may increase infant slippage (RR 1.42, 95% CI 0.67 to 2.99). Subgroup analyses found effects were not modified by age, duration, hereditary risk, filaggrin mutation status, chromosome 11 intergenic variant rs2212434, or intervention type. SCOPE LIMITS: infants only, primary prevention only. Says nothing about emollients as treatment for established eczema, and nothing about adults.Funding / interest: Cochrane Skin, University of Nottingham. Note an evenly-disclosed overlap: several review authors are also investigators on trials included in the review (for example Williams and Boyle on BEEP; Carlsen and Skjerven on PreventADALL; Simpson on the Oregon trial). The full declaration-of-interests statement was not retrieved, only the author list and affiliations.
  3. Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020 Mar 21;395(10228):962-972. PMID 32087126.Tier 2Supports: Multicentre pragmatic parallel-group RCT, 12 UK hospitals and 4 primary care sites, 2014-2016. 1,394 term newborns with a family history of atopic disease randomised (693 emollient, 701 control) to daily whole-body emollient (Diprobase cream or DoubleBase gel) for 12 months plus standard skin-care advice, versus standard advice alone. Intervention started at median age 11 days. Primary outcome, eczema at age 2 by UK Working Party criteria: 'Eczema was present in 139 (23%) of 598 infants... in the emollient group and 150 (25%) of 612 infants in the control group (adjusted relative risk 0.95 [95% CI 0.78 to 1.16], p=0.61).' Skin infections: 'Mean number of skin infections per child in year 1 was 0.23 (SD 0.68) in the emollient group versus 0.15 (0.46) in the control group; adjusted incidence rate ratio 1.55 (95% CI 1.15 to 2.09)', predominantly impetigo. Confirmed food allergy to milk, egg or peanut: 41 (7%) emollient vs 29 (5%) control, adjusted RR 1.47 (95% CI 0.93 to 2.33) — the trial was not powered for this outcome. Adherence 88% (466/532) at 3 months, 82% (427/519) at 6 months, 74% (375/506) at 12 months. Authors' conclusion: 'We found no evidence that daily emollient during the first year of life prevents eczema in high-risk children and some evidence to suggest an increased risk of skin infections.' The interpretation goes further than the package originally recorded and is stated here in full: 'Our study shows that families with eczema, asthma, or allergic rhinitis should not use daily emollients to try and prevent eczema in their newborn.' SCOPE LIMITS: high-risk infants, primary prevention. Basic emollients were used, without ceramides or pH modulation; no emollient was supplied to the control group but self-directed contamination ran at 18% (3 months), 17% (6 months) and 15% (12 months).Funding / interest: NIHR Health Technology Assessment Programme (12/67/12), with additional funding for the food-allergy and sensitisation testing from Goldman Sachs Gives and the Sheffield Children's Hospital Research Fund (CA15008); research nurse support from NIHR Clinical Research Networks; developed with the UK Dermatology Clinical Trials Network. No emollient manufacturer funded the trial. Declaration of interests, verified from the full text: multiple authors reported fees or grants outside the submitted work, including RJB from Dairy Goat Cooperative and DBV Technologies, MJC from Sanofi-Genzyme, Pfizer and LEO Pharma, ELS from AbbVie and Eli Lilly, and CF an EU IMI grant; 'all other authors declare no competing interests'. VERIFIER NOTE: an earlier version of this field named Regeneron and an Imperial College–Nestlé partnership; neither appeared in the retrieved declaration and both have been removed.
  4. Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, et al. Emollients for prevention of atopic dermatitis: 5-year findings from the BEEP randomized trial. Allergy. 2023 Apr;78(4):995-1006. PMID 36263451.Tier 2Supports: Long-term follow-up of the same 1,394 randomised BEEP infants to age 5, via parental questionnaires at 3, 4 and 5 years. Parent-reported clinical diagnosis of atopic dermatitis between 12 and 60 months: 188/608 (31%) emollient group vs 178/631 (28%) control, adjusted relative risk 1.10 (95% CI 0.93 to 1.30). Cumulative incidence of doctor-diagnosed food allergy by 5 years: 92/609 (15%) emollient vs 87/632 (14%) control, adjusted RR 1.11 (95% CI 0.84 to 1.45) — so the earlier food-allergy signal did not persist as doctor-diagnosed allergy, although more emollient-group parents reported food reactions at 3 and 4 years. Asthma and hay fever findings were similar. Authors' conclusion: 'Daily emollient application during the first year of life does not prevent atopic dermatitis, food allergy, asthma or hay fever.' SCOPE LIMITS: outcomes at 3-5 years are parent-reported, not clinician-examined, which is weaker than the 2-year primary outcome.Funding / interest: NIHR Health Technology Assessment Programme, as for the main BEEP trial. Author group overlaps substantially with source 3; the same pharmaceutical declarations apply.
  5. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genetics. 2006 Apr;38(4):441-6. PMID 16550169.Tier 3Supports: The founding genetic-association study. Verbatim: 'two independent loss-of-function genetic variants (R510X and 2282del4) in the gene encoding filaggrin (FLG) are very strong predisposing factors for atopic dermatitis. These variants are carried by approximately 9% of people of European origin. These variants also show highly significant association with asthma occurring in the context of atopic dermatitis.' NOTE ON NOMENCLATURE: the PubMed-indexed abstract renders the first variant as 'R510X'; it is universally cited in subsequent literature as R501X, and the discrepancy appears to be an error in the original abstract. Flagged rather than silently corrected. SCOPE LIMITS: European-ancestry populations; FLG null variant frequency and spectrum differ substantially in other ancestries, so the ~9% carriage figure does not generalise. Effect size in this paper is superseded by the pooled estimate in source 6. The paper does not show that correcting the barrier prevents or cures eczema — that was tested later and failed (sources 2, 3, 4).
  6. Rodríguez E, Baurecht H, Herberich E, Wagenpfeil S, Brown SJ, Cordell HJ, Irvine AD, Weidinger S. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. Journal of Allergy and Clinical Immunology. 2009 Jun;123(6):1361-70.e7. PMID 19501237.Tier 1Supports: Meta-analysis of 24 studies of FLG mutations and eczema (5,791 cases, 26,454 controls, 1,951 families) plus 17 asthma studies (3,138 cases, 17,164 controls, 1,511 offspring). 'Combined analysis showed that FLG haploinsufficiency strongly increases the eczema risk (odds ratio [OR], 3.12; 95% CI, 2.57-3.79) and is associated with more severe and dermatologist-diagnosed disease. FLG mutations are also significantly associated with asthma (OR, 1.48; 95% CI, 1.32-1.66)... although strong effects for the compound phenotype asthma plus eczema (OR, 3.29; 95% CI, 2.84-3.82) were observed, there appears to be no association with asthma in the absence of eczema.' Case-control studies were heterogeneous; family studies more homogeneous. SCOPE LIMITS: predominantly European-ancestry cohorts. An OR of about 3 is a strong risk factor but not determinism: the majority of people with eczema do not carry an FLG null variant, and most carriers of FLG null variants do not have severe disease. Now older than the 2020s literature but remains the definitive pooled effect estimate.
  7. Ridd MJ, Santer M, MacNeill SJ, Sanderson E, Wells S, Webb D, et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial (the BEE trial). Lancet Child & Adolescent Health. 2022 Aug;6(8):522-532. PMID 35617974.Tier 2Supports: Pragmatic individually randomised four-arm phase 4 superiority trial across 77 general practice surgeries in England, 2018-2019. 550 children aged 6 months to 12 years with eczema (POEM >2) randomised 1:1:1:1 to lotion (137), cream (140), gel (135) or ointment (138); initial prescription 500 g or 500 mL twice daily and as required. Baseline median age 4 years, mean POEM 9.3 (SD 5.5); 86% of participants were White. Primary outcome, parent-reported weekly POEM over 16 weeks: 'There was no difference in eczema severity between emollient types over 16 weeks (global p value=0.77)', with all adjusted pairwise POEM differences small and CIs crossing zero (largest, cream vs lotion 0.42, 95% CI -0.48 to 1.32). Total adverse events did not differ (lotions 36%, creams 39%, gels 40%, ointments 35%; p=0.79), 'although stinging was less common with ointments (12 [9%] of 138 participants) than lotions (28 [20%] of 137), creams (24 [17%] of 140), or gels (25 [19%] of 135).' Authors' conclusion: 'Users need to be able to choose from a range of emollients to find one that they are more likely to use effectively.' SCOPE LIMITS: children only; predominantly White cohort; 16 weeks; compared emollient galenic form, not specific active ingredients such as ceramides or urea.Funding / interest: National Institute for Health and Care Research — verified from the PubMed record. No emollient manufacturer funding. VERIFIER NOTE: the declaration-of-interests wording previously quoted verbatim here ('LH currently acts as a consultant for the University of Oxford on an educational grant funded by Pfizer...') could NOT be independently re-verified — thelancet.com, sciencedirect.com and Europe PMC all refused automated retrieval and this paper is not in PMC. Treat the quotation as unconfirmed. Likewise the baseline descriptors below (median age 4 years, mean POEM 9.3, 86% White) come from the full text and could not be re-checked; the randomised arm sizes, global p value, pairwise range and stinging percentages were all re-verified.
  8. Medicines and Healthcare products Regulatory Agency. Topical steroid withdrawal reactions: a review of the evidence. MHRA Public Assessment Report, September 2021.Tier 1Supports: MHRA and Commission on Human Medicines review, triggered by a patient-representative enquiry to the Yellow Card scheme, covering Yellow Card data and a literature review. Conclusions verbatim: 'The review has concluded that when used correctly, topical corticosteroid medicines are safe and effective treatments for skin disorders.' And: 'There is a growing body of evidence that reactions associated with topical steroid withdrawal can occur following long-term or incorrect use of topical corticosteroids, particularly those of moderate to high potency... We are unable to estimate the frequency of these reactions. However, given the number of patients who use topical corticosteroids, we understand reports of severe withdrawal reactions to be very infrequent.' The plain-language summary adds a counterweight that must be quoted alongside it: these effects 'occur very infrequently, however they can be debilitating and long lasting.' Agreed SmPC section 4.4 wording: 'Long term continuous or inappropriate use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome). A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are treated.' Section 4.8 lists withdrawal reactions at frequency 'Not known (cannot be estimated from available data)'. The report distinguishes prescription-only and pharmacy-only topical corticosteroid product-information wording, confirming that in the UK topical corticosteroids are medicines sold as POM or P, never general-sale beauty products; verbatim, 'mild corticosteroids, such as hydrocortisone, can be bought over the counter from pharmacies for use in older children and adults, whereas stronger or more potent types of corticosteroids are only available on prescription. Corticosteroids for skin problems in children younger than 10 years are available only on prescription.' IMPORTANT LIMIT the MHRA states itself: Yellow Card report counts cannot be used to determine incidence, and MedDRA has no coding term for topical steroid withdrawal, which made case identification difficult.
  9. Long CC, Finlay AY. The finger-tip unit — a new practical measure. Clinical and Experimental Dermatology. 1991 Nov;16(6):444-7. PMID 1806320.Tier 3Supports: The primary source for the fingertip unit. Verbatim: 'A finger-tip unit (FTU) is the amount of ointment expressed from a tube with a 5 mm diameter nozzle, applied from the distal skin-crease to the tip of the index finger.' Thirty adult patients treated anatomical regions using FTUs of ointment. FTUs required: face and neck 2.5 (SD 0.8); front of trunk 6.7 (1.7); back of trunk 6.8 (1.2); arm and forearm 3.3 (1.0); hand 1.2 (0.4); leg and thigh 5.8 (1.7); foot 1.8 (0.6). 'One FTU covers 286 cm2 (s.d. +/- 80, n = 30). In males one FTU covers 312 cm2 (s.d. +/- 90, n = 16) and in females 257 cm2 (s.d. +/- 55, n = 14).' SCOPE LIMITS: 30 adults, ointment only, 5 mm nozzle assumed; the standard deviations are wide (roughly 28% of the mean area). Paediatric FTU charts in current use are extrapolations from this adult work, not separately validated here. No funding statement in the record.
  10. Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatology. 2017 Oct 1;153(10):1036-1042. PMID 28724128.Tier 1Supports: Systematic review of literature from January 1946 to October 2016; 490 articles screened, 16 met eligibility criteria. 'All studies were cross-sectional. Topical corticosteroid phobia prevalence ranged from 21.0% (95% CI, 15.8%-26.2%) to 83.7% (95% CI, 81.9%-85.5%).' 'In the 2 studies that compared nonadherence between a phobia group and a nonphobia group, patients in both phobia groups were found to have a significantly higher rate of nonadherence (49.4% vs 14.1% and 29.3% vs 9.8%).' Information sources named by patients included 'physicians, friends and relatives, broadcast media, print media, and the internet.' IMPORTANT SCOPE LIMIT stated by the authors: definitions ranged 'from concern to irrational fear', questionnaires ranged from 1 to 69 questions, and the lack of standardisation 'preclud[es] quantitative comparison and extrapolation of data'. So this is a tier-1 systematic review of tier-3-quality cross-sectional evidence: the phenomenon is real and widespread, the range is too wide to quote a single prevalence figure, and the adherence association is from only two studies and is correlational.
  11. Jensen MB, Kursawe Larsen C, Hamann CR, Johansen JD, Quaade AS. Association Between Atopic Dermatitis and Contact Sensitization: An Updated Systematic Review and Meta-Analysis. Contact Dermatitis. 2026 Mar;94(3):201-225. Epub 21 December 2025. PMID 41423749.Tier 1Supports: Systematic search of PubMed, Embase and Web of Science for studies published 2016-2025 reporting contact sensitisation prevalence in people with and without atopic dermatitis, pooled with the earlier 1982-2016 review (Hamann et al, JAAD 2017;77:70-78, which found OR 0.891, 95% CI 0.771-1.03). Updated pooled result: 'no overall association between AD and CS (OR 1.08, 95% CI: 0.82-1.42), including in referred populations (OR 1.03, 95% CI: 0.76-1.38). In general population studies, CS prevalence was higher among individuals with AD. The association was statistically significant in children and adolescents (OR 1.34, 95% CI: 1.0-1.80) but not in adults. Positive associations were found between AD and CS to Compositae mix and sesquiterpene lactone mix, but not to nickel, cobalt, or chromium.' Authors conclude the findings underline 'the value of patch testing in AD'. SCOPE LIMITS: contact sensitisation measured by patch testing, which is not the same as clinically relevant allergic contact dermatitis; allergen panels varied between studies; referred populations are selected. No study in this body of work specifically examined salon or professional-treatment product exposures.Funding / interest: Funded by the Danish Environmental Protection Agency under the Ministry of Environment of Denmark. Lead group is the National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, with the University of Copenhagen. DISCLOSURE THE PACKAGE ORIGINALLY MISSED: co-author Carsten R Hamann is affiliated to the Contact Dermatitis Institute, Phoenix, Arizona — a commercial contact-allergen and patch-testing enterprise — as well as Dartmouth-Hitchcock Medical Center. The review's stated conclusion is that the findings underline 'the value of patch testing in AD', so an author has a commercial interest in the intervention the conclusion endorses. Hamann is also first author of the 2017 review this one updates. The itemised per-author competing-interests statement sits behind Wiley's paywall and was not retrieved; the affiliation is from the MEDLINE record.
  12. Chowdhury M (President, British Association of Dermatologists), Chua S-L, Flohr C, Pink A, McPherson T, Roberts G, Cunliffe T, Penzer-Hick R, Proctor A, Yates G, Warner A, et al. Letter to Professor Jonathan Benger, Chief Medical Officer and Interim Director of the Centre for Guidelines, NICE: 'NICE clinical guideline for managing adults and adolescents with atopic dermatitis (AD)'. 22 June 2023.Tier 4Supports: Joint letter with THIRTEEN signatories representing EIGHT professional bodies and patient charities — British Association of Dermatologists, British Society for Paediatric and Adolescent Dermatology, British Society for Allergy and Clinical Immunology, Primary Care Dermatology Society, British Dermatological Nursing Group, National Eczema Society, Eczema Outreach Support and Allergy UK — plus academic signatories in their own right (Flohr as TREAT chief investigator, Pink as BEACON chief investigator, Chua as chair of the BAD Therapy & Guidelines sub-committee, Kim Thomas for the Centre of Evidence Based Dermatology at Nottingham, Matthew Ridd for SAPC and the University of Bristol). It is NOT eleven bodies; that count has been corrected. Verbatim: NICE informed them that development of the 'long-awaited clinical guideline' for adults and adolescents with atopic dermatitis, planned in collaboration with the BAD, 'has been 'stopped for the time being'', with 'no guarantee that the project will resume'. Prevalence figure as stated by the signatories: 'Atopic dermatitis is a chronic condition affecting around 20% of children and 10% of adults in the UK, with a quality-of-life, psychological and economic burden similar to other chronic health conditions, such as asthma and diabetes', citing Laughter et al, Br J Dermatol 2021;184:304-9. They add: 'The absence of a guideline has resulted in variances in treatment and referral approaches' and note that in the 15 years since CG57, 'nearly £15.5 million have been awarded by the National Institute for Health and Care Research (NIHR) for eczema studies... Yet, none of the practice-changing results... have been reflected in any guideline.' The letter's appendix tabulates those NIHR studies with funders and amounts — SWET, CREAM, CLOTHES and others — and is the document that settles the 'CREAM trial' question recorded in notFound. SCOPE LIMITS: this is an advocacy letter from professional bodies, not a guideline or a systematic review. The prevalence figures are secondary citations. Tier 4 accordingly. Its load-bearing value is as documentary evidence of the guideline gap, which is verifiable and not a matter of opinion.
  13. British Association of Dermatologists. Atopic Eczema. BAD Patient Information Leaflet, updated July 2020, links revised May 2022.Tier 4Supports: This is a patient information leaflet, not a clinical guideline — the BAD has no published clinical guideline for the management of atopic eczema. Verbatim content used here: 'It is estimated that up to 1 in 5 children will be affected by eczema at some point.' On emollients: 'Complete emollient therapy is the most important treatment for all patients affected by eczema... The best one to use is the greasiest one you are prepared to apply.' On aqueous cream: 'Aqueous cream was originally developed as a soap substitute. It is often used as a moisturiser but can irritate the skin and make atopic eczema worse. For this reason, it is recommended that aqueous cream is not used as a moisturiser.' On fingertip units: 'Use a fingertip unit (squeeze steroid from the tube to cover the length of your index fingertip – about 1 inch) to cover the same area of skin as two hands laid flat with the fingers together.' On steroid safety: 'Used appropriately, topical steroids are very effective and safe to use. Used inappropriately (too strong or for too long and on the wrong body site), topical steroids may cause side effects, including thinning of the skin. However, insufficient treatment with topical steroids is generally considered by doctors to be more of a problem than overuse.' On infected skin: topical calcineurin inhibitors 'are associated with an increased risk of skin infections and should not be applied to infected (weeping, crusted) skin.' On unregulated products: 'It is recommended that 'natural' herbal creams are not purchased as they can cause irritation and allergic reactions. Some so-called natural creams have been shown to contain potent steroids. Other herbal creams have been shown to contain high levels of harmful bacteria including MRSA.' Triggers listed: 'irritants such as soaps, detergents and other chemicals, heat, dust, woollen clothing, and pets.' SCOPE LIMITS: patient-facing leaflet, expert opinion, no evidence grading, no references to underlying trials. The 'undertreatment is more of a problem than overuse' statement is explicitly framed as what doctors generally consider — it is clinical opinion, not a measured comparison.
  14. Department of Health and Social Care. Licensing of non-surgical cosmetic procedures (consultation). Opened 2 September 2023, closed 28 October 2023; consultation outcome published 7 August 2025.Tier 1Supports: DHSC consultation on a licensing scheme for non-surgical cosmetic procedures in England. Its 2023 consultation document set out a proposed three-tier, risk-based (green/amber/red) classification of procedures — a PROPOSAL only. The August 2025 consultation outcome committed to introducing 'legal restrictions which will ensure that cosmetic procedures which are deemed to pose the highest level of risk to the public (such as liquid Brazilian butt lifts) are classed as Care Quality Commission (CQC) regulated activities', to local authority licensing for lower-risk procedures, and to age restrictions, with further public consultation planned. Crucially: 'The proposals will be taken forward through secondary legislation and therefore subject to the Parliamentary process before the legal restrictions or licensing regulations can be introduced.' NO LICENSING SCHEME IS IN FORCE. Individual procedure-to-tier assignments come from the 2023 consultation document only; the 2025 response does not assign them. SCOPE LIMIT: England only, and it concerns who may perform cosmetic procedures — it does not create any authority for a non-medical practitioner to diagnose or treat atopic dermatitis, which is separately governed by medicines and professional-regulation law.